Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021GlobeNewsWire • 09/20/21
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?Zacks Investment Research • 09/20/21
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 08/12/21
Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy TrialsBenzinga • 08/06/21
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy ProgramsGlobeNewsWire • 08/05/21
Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-TransplantBenzinga • 07/21/21
Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemiaGlobeNewsWire • 06/17/21
APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing TodayInvestorPlace • 06/16/21
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia PatientsBenzinga • 06/16/21
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease SummitGlobeNewsWire • 05/21/21
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/18/21
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 05/06/21
Karolinska Development's portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AMLGlobeNewsWire • 04/09/21
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewsWire • 04/08/21